Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Archives of Neurology · 01.09.2011 · 68 (9) · 1156
DOI: 10.1001/archneurol.2011.103 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Archives of Neurology, erschienen am 01.09.2011. Verfasst von David B Clifford und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University, St Louis, MO 63110, USA. cliffordd@neuro.wustl.edu. Die Arbeit wurde bisher 239-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINR NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Objective
To describe the development of progressive multifocal leukoencephalopathy (PML) in patients with rheumatoid arthritis (RA) treated with rituximab.
Design
Case study.
Setting
Clinical care for patients with rheumatologic diseases. Most were referred to academic centers for care after diagnosis (Washington University, St Louis, Missouri; Karolinska Insitute, Stockholm, Sweden; and Royal Melbourne Hospital, Melbourne, Australia) while one was cared for in a neurology practice in Dallas, Texas, with consultation by an academic neurovirologist from the University of Colorado in Denver. Patients Four patients developing PML in the setting of rituximab therapy for RA.
Intervention
Rituximab therapy. Main Outcome Measures Clinical and pathological observations.
Results
Four patients from an estimated population of 129 000 exposed to rituximab therapy for RA are reported in whom PML developed after administration of this drug. All were women older than 50 years, commonly with Sjögren syndrome and a history of treatment for joint disease ranging from 3 to 14 years. One case had no prior biologic and minimal immunosuppressive therapy. Progressive multifocal leukoencephalopathy presented as a progressive neurological disorder, with diagnosis confirmed by detection of JC virus DNA in the cerebrospinal fluid or brain biopsy specimen. Two patients died in less than 1 year from PML diagnosis, while 2 remain alive after treatment withdrawal. Magnetic resonance scans and tissue evaluation confirmed the frequent development of inflammatory PML during the course of the disease.
Conclusion
These cases suggest an increased risk, about 1 case per 25 000 individuals, of PML in patients with RA being treated with rituximab. Inflammatory PML may occur in this setting even while CD20 counts remain low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Washington University, St Louis, MO 63110, USA. cliffordd@neuro.wustl.edu
Förderung
- NIA NIH HHS
- NINR NIH HHS
- NCATS NIH HHS
Zitieren
APA
Clifford, D. B., Ances, B., Costello, C., Rosen-Schmidt, S., Andersson, M., Parks, D., Perry, A., Yerra, R., Schmidt, R., Alvarez, E., & Tyler, K. L. (2011). Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. Archives of Neurology, 68(9), 1156. https://doi.org/10.1001/archneurol.2011.103
Vancouver
Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. Archives of Neurology. 2011;68(9):1156. doi:10.1001/archneurol.2011.103
BibTeX
@article{Clifford2011,
author = {Clifford, David B and Ances, Beau and Costello, Craig and Rosen-Schmidt, Shari and Andersson, Magnus and Parks, Deborah and Perry, Arie and Yerra, Raju and Schmidt, Robert and Alvarez, Enrique and Tyler, Kenneth L},
title = {Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis},
journal = {Archives of Neurology},
year = {2011},
volume = {68},
number = {9},
pages = {1156},
doi = {10.1001/archneurol.2011.103}
}
EUVIMED